Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02561247 · ClinicalTrials.gov registry record · NA
Prismaflex HF20 Set and Prismaflex® System 7.10/7.20 for Acute Continuous Renal Replacement Therapy (CRRT) in Children
A NA study, sponsored by Vantive Health.
- Terminated
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT02561247 is a NA study that was terminated before completion, run by Vantive Health. The registered enrollment target is 23 participants.
The verdict
NCT02561247, a NA study, was terminated before completion, sponsored by Vantive Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of the Gambro Prismaflex® HF20 Set based on testing the hypothesis that it delivers sufficient renal replacement therapy to effectively treat acute kidney injury (AKI) in pediatric patients by reducing blood urea nitrogen (BUN).
Interventions
- DEVICE Prismaflex HF20 CRRT Filter
- DEVICE Prismaflex® System 7.10 and 7.20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-11-10 |
| Est. Completion | 2018-04-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02561247
The ClinicalTrials.gov registry entry for NCT02561247 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vantive Health, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prismaflex HF20 CRRT Filter is the first listed.
NCT02561247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02561247 about?
NCT02561247 is a clinical study titled "Prismaflex HF20 Set and Prismaflex® System 7.10/7.20 for Acute Continuous Renal Replacement Therapy (CRRT) in Children". The primary objective of this study is to evaluate the efficacy of the Gambro Prismaflex® HF20 Set based on testing the hypothesis that it delivers sufficient renal replacement therapy to effectively treat acute kidney injury (AKI) in pediatric patients by reducing blood urea nitrogen (BUN).
What is the current status of trial NCT02561247?
This trial is currently terminated. It is a NA study. The enrollment target is 23 participants. The study started on 2015-11-10. Estimated completion is 2018-04-06.
What interventions are being tested in trial NCT02561247?
The interventions under investigation include: Prismaflex HF20 CRRT Filter (DEVICE), Prismaflex® System 7.10 and 7.20 (DEVICE).
Who is sponsoring clinical trial NCT02561247?
This trial is sponsored by Vantive Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.